REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
European Organisation for Research and Treatment of Cancer - EORTC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of MF-CTCL stage IA or IB at enrolment as per ISCL/EORTC revision to the MF and Sézary syndrome classification and MF stage should have never met the criteria for stage IIA or higher in the patient medical history
Lesions cover less than 80% of BSA
Age ≥ 18
ECOG/WHO performance status 0-2
You may not be if
Previous treatment with CL gel
Concurrent or planned local or systemic anti-CTCL therapy
Prior treatment with antihistamines or narrow band UV-B or PUVA therapy one week before enrolment, or systemic corticosteroids or radiotherapy in the last 4 weeks before enrolment
Prior treatment with topical steroids in the patch test area (upper back) one week before enrolment
Clareo Health | REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)
